U.S., July 15 -- ClinicalTrials.gov registry received information related to the study (NCT07703462) titled 'Personalized Antisense Oligonucleotide Therapy for a Participant With TARDBP ALS' on July 09.
Brief Summary: This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in TARDBP.
Study Start Date: Dec., 2026
Study Type: INTERVENTIONAL
Condition:
Amyotrophic Lateral Sclerosis (ALS)
Intervention:
DRUG: nL-TARDB-002
Personalized antisense oligonucleotide
Recruitment Status: ENROLLING_BY_INVITATION
Sponsor: n-Lorem Foundation
Published by HT Digital Content Services with permission from Heal...